Jefferies Johanna M C, Macdonald Emily, Faust Saul N, Clarke Stuart C
Faculty of Medicine, University of Southampton, Southampton, UK.
Hum Vaccin. 2011 Oct;7(10):1012-8. doi: 10.4161/hv.7.10.16794. Epub 2011 Oct 1.
The thirteen valent pneumococcal conjugate vaccine (PCV13, Prevenar 13(TM)) is the broader coverage successor to the highly effective seven valent vaccine (PCV7, Prevenar(TM)) which has reduced rates of pneumococcal disease in many countries. Despite the success of PCV7, pneumococcal disease due to non-PCV7 serotypes remains a threat in many settings, in particular many developing countries with a high burden of pneumococcal disease where serotype 1 and 5 are among the most common serotypes. Disease due to certain non-PCV7 serotypes, in particular serotype 19A has also begun to increase in incidence in countries with widespread use of PCV7. PCV13 consists of thirteen pneumococcal capsular polysaccharides individually conjugated to the diphtheria-derived protein carrier CRM(197). In addition to serotypes 4, 6B, 9V, 14, 18C, 19F and 23F included in PCV7, PCV13 also includes serotypes 1, 3, 5, 6A, 7F and 19A. PCV13 was licensed on the basis of non-inferiority trials and has proved to be at least as safe and effective as PCV7. PCV13 replaced PCV7 in the childhood immunisation schedules of the USA and UK in 2010 and is being rolled out to an increasing number of developing countries during 2011. Here we review the current literature regarding this vaccine, describing safety, efficacy, global serotype coverage and use and future directions.
13价肺炎球菌结合疫苗（PCV13，沛儿13TM）是高效7价疫苗（PCV7，沛儿TM）覆盖面更广的后续产品，PCV7已在许多国家降低了肺炎球菌疾病的发病率。尽管PCV7取得了成功，但在许多情况下，尤其是在肺炎球菌疾病负担较高的许多发展中国家，由非PCV7血清型引起的肺炎球菌疾病仍然是一个威胁，其中1型和5型是最常见的血清型。在PCV7广泛使用的国家，由某些非PCV7血清型，特别是19A血清型引起的疾病发病率也开始上升。PCV13由13种肺炎球菌荚膜多糖分别与源自白喉的蛋白质载体CRM(197)结合而成。除了PCV7中包含的4、6B、9V、14、18C、19F和23F血清型外，PCV13还包括1、3、5、6A、7F和19A血清型。PCV13是根据非劣效性试验获得许可的，并且已被证明至少与PCV7一样安全有效。2010年，PCV13在美国和英国的儿童免疫接种计划中取代了PCV7，并在2011年推广到越来越多的发展中国家。在此，我们综述了关于该疫苗的当前文献，描述了其安全性、有效性、全球血清型覆盖范围、使用情况及未来发展方向。
